Cite
HARVARD Citation
Merz, V. et al. (2020). A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal–gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial. Therapeutic advances in medical oncology. p. . [Online].